Showing results (111-120 of 164) with videos related to
Sort By:
Pageof 17
Signal Transduction and Targeted Therapy|December 1, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinibYuankai Shi, Dongqing Lv, Weineng Feng, et al.Journal of Translational Medicine|December 12, 2025
Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancerJiacheng Dai, Huan Yan, Yangqian Chen, et al.Neoplasia (New York, N.Y.)|June 14, 2021
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancerLing Tian, Congcong Chen, Yanguan Guo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2020
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLCYongchang Zhang, Liang Zeng, Chunhua Zhou, et al.Lung Cancer (Amsterdam, Netherlands)|January 27, 2020
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world populationLiang Zeng, Lili Xiao, Wenjuan Jiang, et al.Heliyon|January 6, 2025
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastasesLiqun Li, Zhe Huang, Yangqian Chen, et al.Cell Reports. Medicine|June 30, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trialHuan Yan, Wenjuan Jiang, Yi Xiong, et al.Journal of the National Cancer Institute|March 11, 2021
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor TherapyYing Jing, Yongchang Zhang, Jing Wang, et al.Recent Patents on Anti-Cancer Drug Discovery|July 3, 2026
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of NHWD-870 HCl in Patients with Lymphoma and Other Advanced Solid TumorsMingzhu Yin, Xin Li, Zhuomiao Ye, et al.JCO Precision Oncology|March 23, 2023
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort StudyZhe Huang, Huan Yan, Liang Zeng, et al.Pageof 17